These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32909330)

  • 21. Adverse effects of proton pump inhibitors: fact or fake news?
    Schubert ML
    Curr Opin Gastroenterol; 2018 Nov; 34(6):451-457. PubMed ID: 30102612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis.
    Wijarnpreecha K; Thongprayoon C; Chesdachai S; Panjawatanana P; Ungprasert P; Cheungpasitporn W
    Dig Dis Sci; 2017 Oct; 62(10):2821-2827. PubMed ID: 28836158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proton pump inhibitors use and risk of chronic kidney disease in diabetic patients.
    Yang H; Juang SY; Liao KF
    Diabetes Res Clin Pract; 2019 Jan; 147():67-75. PubMed ID: 30500543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Proton pump inhibitors and kidney].
    Desbuissons G; Deray G; Mercadal L
    Nephrol Ther; 2018 Apr; 14 Suppl 1():S115-S124. PubMed ID: 29274872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis.
    Nochaiwong S; Ruengorn C; Awiphan R; Koyratkoson K; Chaisai C; Noppakun K; Chongruksut W; Thavorn K
    Nephrol Dial Transplant; 2018 Feb; 33(2):331-342. PubMed ID: 28339835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proton pump inhibitors are associated with lower magnesium levels in older people with chronic kidney disease.
    Sumukadas D; McMurdo ME; Habicht D
    J Am Geriatr Soc; 2012 Feb; 60(2):392-3. PubMed ID: 22332695
    [No Abstract]   [Full Text] [Related]  

  • 27. Proton pump inhibitor use and progression to major adverse renal events: a competing risk analysis.
    Grant CH; Gillis KA; Lees JS; Traynor JP; Mark PB; Stevens KI
    QJM; 2019 Nov; 112(11):835-840. PubMed ID: 31251364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proton Pump Inhibitors and CKD: The Evidence Builds.
    Grams ME; Wilson FP
    J Am Soc Nephrol; 2024 Jul; 35(7):833-834. PubMed ID: 38809613
    [No Abstract]   [Full Text] [Related]  

  • 29. [Prevention of iatrogenic risk and screening of chronic kidney disease].
    Vasmant D
    Nephrol Ther; 2019 Nov; 15(6):465-467. PubMed ID: 31636049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interpreting Reported Risks Associated With Use of Proton Pump Inhibitors: Residual Confounding in a 10-Year Analysis of National Ambulatory Data.
    Ma C; Shaheen AA; Congly SE; Andrews CN; Moayyedi P; Forbes N
    Gastroenterology; 2020 Feb; 158(3):780-782.e3. PubMed ID: 31678304
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-term Renal Effects of Proton Pump Inhibitor Use.
    Lazarus B; Carrero JJ
    Gastroenterology; 2020 Mar; 158(4):1173-1174. PubMed ID: 31836527
    [No Abstract]   [Full Text] [Related]  

  • 32. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.
    Moayyedi P; Eikelboom JW; Bosch J; Connolly SJ; Dyal L; Shestakovska O; Leong D; Anand SS; Störk S; Branch KRH; Bhatt DL; Verhamme PB; O'Donnell M; Maggioni AP; Lonn EM; Piegas LS; Ertl G; Keltai M; Cook Bruns N; Muehlhofer E; Dagenais GR; Kim JH; Hori M; Steg PG; Hart RG; Diaz R; Alings M; Widimsky P; Avezum A; Probstfield J; Zhu J; Liang Y; Lopez-Jaramillo P; Kakkar A; Parkhomenko AN; Ryden L; Pogosova N; Dans A; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik T; Vinereanu D; Tonkin AM; Lewis BS; Felix C; Yusoff K; Metsarinne K; Fox KAA; Yusuf S;
    Gastroenterology; 2019 Aug; 157(2):403-412.e5. PubMed ID: 31054846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PPIs and kidney disease: from AIN to CKD.
    Moledina DG; Perazella MA
    J Nephrol; 2016 Oct; 29(5):611-6. PubMed ID: 27072818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease.
    Arora P; Gupta A; Golzy M; Patel N; Carter RL; Jalal K; Lohr JW
    BMC Nephrol; 2016 Aug; 17(1):112. PubMed ID: 27487959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Proton Pump Inhibitor Use With Serum Biomarkers of Inflammation, Insulin Resistance, Cardiovascular Risk, and Renal Function.
    Austin GL; Weiskopf JR; Czwornog JL
    J Clin Gastroenterol; 2018 Sep; 52(8):691-695. PubMed ID: 29099466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What Is the Optimal Follow-up Time to Ascertain the Safety of Proton Pump Inhibitors?
    Losurdo G; Di Leo A; Leandro G
    Gastroenterology; 2020 Mar; 158(4):1175. PubMed ID: 31884072
    [No Abstract]   [Full Text] [Related]  

  • 37. Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome.
    Singh A; Cresci GA; Kirby DF
    Nutr Clin Pract; 2018 Oct; 33(5):614-624. PubMed ID: 30071147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proton pump inhibitors, adverse events and increased risk of mortality.
    Lanas-Gimeno A; Hijos G; Lanas Á
    Expert Opin Drug Saf; 2019 Nov; 18(11):1043-1053. PubMed ID: 31498687
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety and Complications of Long-Term Proton Pump Inhibitor Therapy: Getting Closer to the Truth.
    Corley DA
    Gastroenterology; 2019 Sep; 157(3):604-607. PubMed ID: 31378636
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of low-dose proton pump inhibitor on preventing upper gastrointestinal bleeding in chronic kidney disease patients receiving aspirin.
    Lim H; Kim JH; Baik GH; Park JW; Kang HS; Moon SH; Park CK
    J Gastroenterol Hepatol; 2015 Mar; 30(3):478-84. PubMed ID: 25252119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.